Acadia Pharmaceuticals (ACAD) Gross Margin (2016 - 2026)
Acadia Pharmaceuticals' quarterly Gross Margin came in at 90.75% in Q1 2026, down 90.0% year-on-year from 907.52% in Q1 2025, and little changed quarter-over-quarter from 90.77% in Q4 2025.
Acadia Pharmaceuticals has reported Gross Margin for 11 years, with the latest figure at 90.75% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin fell 90.0% year-over-year to 90.75%; the trailing twelve-month figure through Mar 2026 stood at 91.47% (down 57.0% YoY), and the FY2025 full-year result was 91.69%, up 24.0% from the prior year.
- Gross Margin for Q1 2026 stood at 90.75%, roughly flat from 90.77% in the prior quarter.
- The five-year high for Gross Margin was 98.59% in Q1 2023, with the low at 88.85% in Q1 2024.
- Average Gross Margin over 5 years is 93.79%, with a median of 92.47% recorded in 2024.
- Year-over-year, Gross Margin surged 645 bps in 2022 and plunged 974 bps in 2024.
- Tracing ACAD's Gross Margin over 5 years: stood at 98.23% in 2022, then decreased by 6 bps to 92.26% in 2023, then slipped by 1 bps to 91.6% in 2024, then retreated by 1 bps to 90.77% in 2025, then fell by 0 bps to 90.75% in 2026.
- The last three Gross Margin figures came in at 90.75% (Q1 2026), 90.77% (Q4 2025), and 92.23% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 86.85% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 91.79% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 82.22% |
| 10 | Acadia Pharmaceuticals | 3.69 Bn | 2.84 Bn | 243.27 Mn | 90.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 90.75% |
| Dec 31, 2025 | 90.77% |
| Sep 30, 2025 | 92.23% |
| Jun 30, 2025 | 92.16% |
| Mar 31, 2025 | 91.65% |
| Dec 31, 2024 | 91.60% |
| Sep 30, 2024 | 92.47% |
| Jun 30, 2024 | 92.47% |
| Mar 31, 2024 | 88.85% |
| Dec 31, 2023 | 92.26% |
| Sep 30, 2023 | 93.09% |
| Jun 30, 2023 | 95.49% |
| Mar 31, 2023 | 98.59% |
| Dec 31, 2022 | 98.23% |
| Sep 30, 2022 | 98.37% |
| Jun 30, 2022 | 98.02% |
| Mar 31, 2022 | 97.45% |
| Dec 31, 2021 | 91.78% |
| Sep 30, 2021 | 97.20% |
| Jun 30, 2021 | 97.81% |
| Mar 31, 2021 | 97.95% |
| Dec 31, 2020 | 97.93% |
| Sep 30, 2020 | 98.34% |
| Jun 30, 2020 | 97.37% |
| Mar 31, 2020 | 96.89% |
| Dec 31, 2019 | 96.93% |
| Sep 30, 2019 | 97.45% |
| Jun 30, 2019 | 96.44% |
| Mar 31, 2019 | 95.31% |
| Dec 31, 2018 | 95.26% |
| Sep 30, 2018 | 93.42% |
| Jun 30, 2018 | 93.76% |
| Mar 31, 2018 | 95.59% |
| Dec 31, 2017 | 94.36% |
| Sep 30, 2017 | 94.00% |
| Jun 30, 2017 | 92.70% |
| Mar 31, 2017 | 85.20% |
| Dec 31, 2016 | 85.75% |
| Sep 30, 2016 | 83.96% |
| Jun 30, 2016 | -442.27% |